AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Barclays PLC

Barclays PLC grew its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 117.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 44,300 shares of the biotechnology company’s stock after purchasing an additional 23,926 shares during the period. Barclays PLC’s holdings in AnaptysBio were worth $1,486,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. lifted its position in AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after acquiring an additional 1,265,891 shares during the last quarter. FMR LLC lifted its holdings in shares of AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of AnaptysBio in the 3rd quarter valued at about $8,874,000. Victory Capital Management Inc. boosted its position in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after buying an additional 168,813 shares during the last quarter.

AnaptysBio Trading Down 5.1 %

NASDAQ ANAB opened at $13.04 on Friday. The stock has a market capitalization of $396.79 million, a price-to-earnings ratio of -2.14 and a beta of -0.11. The business’s 50 day moving average is $21.79 and its two-hundred day moving average is $28.83. AnaptysBio, Inc. has a 12-month low of $13.00 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities analysts forecast that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ANAB. Wells Fargo & Company reduced their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. lowered their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and reduced their target price for the company from $52.00 to $19.00 in a report on Wednesday, December 11th. Finally, Guggenheim lowered their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.45.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.